Dr. Matthew S. Clary, MD

Dr. Clary practices at Uchealth Ccmc Infusion Outpatient - Chemotherapy - HOPD in Denver, Colorado.

Dr. Clary's NPI, 1033374053, was assigned on July 21, 2008. Dr. Clary graduated from Ohio State College of Medicine in 2006. Dr. Clary holds Colorado license 51069.

Dr. Clary's primary practice is Uchealth Ccmc Infusion Outpatient - Chemotherapy - HOPD, at 100 Cook St, Denver, CO 80206.

Dr. Clary's primary practice is Uchealth Ccmc Infusion Outpatient - Chemotherapy - HOPD in Denver, Colorado. Dr. Clary is also affiliated with National Jewish Health. The medical group on file is University of Colorado Medicine (CU Medicine). Dmand AI also links Dr. Clary to 1 more hospital, 2 medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Clary practices, 4 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Clary's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Clary is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Clary's licenses on file in 5 states: Colorado, California, Pennsylvania, District of Columbia and Virginia.

Dmand AI lists larynx and vocal cord disease and upper respiratory infection (URI) among the conditions Dr. Clary treats.

CMS data shows 872 Medicare services from Dr. Clary across 10 procedure codes in 2024, for 374 Medicare patients. Medicare paid $116,661 for them.

CMS counts 374 Medicare patients who saw Dr. Clary in 2024. The largest group is 65 to 74, with 200 patients. 71% of them have high cholesterol, and 58% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Clary's median patient age at 70, with 61% women.

In 2024, Dr. Clary wrote 190 Medicare Part D claims for 89 patients. 99% of them were for generic drugs. CMS names the drug for 152 of them, across 5 drugs with 11 or more claims each, at $1,815 in total drug cost. In 2023, CMS named 103 claims across 6 drugs.

Dr. Clary accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Clary as offering telehealth. CMS counts 11 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Clary, more than 42% of the clinicians it reports for that procedure.

Dmand AI links 28 papers to Dr. Clary, published from 2011 to 2024. 2017 was the busiest year, with 3. The most frequent topics are Chemoreceptor Cells, Equipment Design and Laryngeal Diseases. Dr. Clary has published most often in Laryngoscope. Dr. Clary's most frequent co-authors are Paul Bryson, MD, David Gary Lott, MD and James J. Daniero, MD.

Dmand AI links Dr. Clary to 1 clinical trial. Conditions studied include Idiopathic subglottic tracheal stenosis.

CMS Open Payments shows 4 general payments to Dr. Clary from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Olympus America Inc. paid the most, $361.

Dmand AI lists 2 awards for Dr. Clary, most recently CMS Stage 1 EHR in 2013.

Dr. Clary graduated from Ohio State College of Medicine in 2006. Dr. Clary is a member of NHS.

Dr. Clary is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.